After positive top-line results of pain med, Trevena shares fall 30%

Despite announcing that its candidate pain med oliceridine had met its primary end-points in a pivotal trial, USA-based Trevena's (Nasdaq: TRVN) shares dropped sharply on concerns that the results weren’t good enough.

Oliceridine, a candidate therapy for moderate-to-severe acute pain following bunionectomy and abdominoplasty was found to cause a statistically greater analgesic efficacy than placebo.

The drug also showed improvement against morphine on measures of respiratory safety and gastrointestinal tolerability.